fda compounding semaglutide crackdown news today 2025 The announced plans to take action against non-FDA-approved GLP-1 receptor agonists, a move that prompted telehealth company Hims & Hers to yank its new compounded (Wegovy) weight-loss pill from the FDA GLP-1 Compounding Crackdown

Experts to reveal results of retatrutide trials TRANSCEND-T2D-1 and TRIUMPH-1 Jonathan Campbell, PhD, and other panelists will share new data and address how this triple-hormone receptor agonist may unlock the next frontier of treatment for obesity and type 2 diabetes

As new approved indications for GLP-1s continue to emerge, including uses related to cardiovascular disease and obstructive sleep apnea, more patients qualify for the medication

But both can be prescribed for other off-label uses

This suggests that GLP-1R-Gs activation rescues insulin secretion inhibited by pasireotide through the activation of SSTRs-Gi in GLP-1R-MIN-6 cells (Fig

The commercial dosing may differ when the drug eventually launches